Compare Canadian Natural Resources Ltd. (CNQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Merck & Co., Inc. — how do they compare? Canadian Natural Resources Ltd. trades at $42.74 (market cap $88.15B), while Merck & Co., Inc. trades at $124.01 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 3.4× Canadian Natural Resources Ltd.'s market cap, and Canadian Natural Resources Ltd. pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| CNQ | MRK | |
|---|---|---|
Market Cap | $88.15B | $298.31B |
Sector | Energy | Health |
52-Week High | $50.55 | $129.52 |
52-Week Low | $29.31 | $77.60 |
Enterprise Value | $99.38B | $341.72B |
Dividend Yield | 4.13% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNQ trades at $43.05, up 2.97% today, with a bullish technical signal supported by moving averages and ADX. The stock shows strong fundamentals with a P/E of 11.8, net income margin of 24.5%, and consistent earnings beats in recent quarters. Recent news highlights its robust asset base and operational efficiency amid volatile oil markets. Cash flow remains positive, with 2025 net cash flow at $542 million.
Outlook is positive with analyst consensus strongly favoring Buy (75%), driven by valuation appeal and shareholder returns via dividends and buybacks. Key risks include oil price volatility and rising debt-to-asset ratio, which increased to 22.04% in 2024. The stock's proximity to its 52-week high suggests cautious optimism, but fundamentals support long-term growth potential.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
